Skip to main content

NICE TAs

28/07/2020
TA330: Sofosbuvir for treating chronic hepatitis C
28/07/2020
TA458: Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane (replaced TA371)
28/07/2020
TA352: Vedolizumab for treating moderately to severely active Crohn's disease after prior therapy
28/07/2020
TA342: Vedolizumab for treating moderately to severely active ulcerative colitis
28/07/2020
TA336: Empagliflozin in combination therapy for treating type 2 diabetes
24/07/2020
TA327: Dabigatran etexilate for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
24/07/2020
TA343: Obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
24/07/2020
TA254: Fingolimod for the treatment of highly active relapsing–remitting multiple sclerosis
24/07/2020
TA347: Nintedanib for previously treated locally advanced, metastatic, or locally recurrent non‑small‑cell lung cancer
24/07/2020
TA341: Apixaban for the treatment and secondary prevention of deep vein thrombosis and/or pulmonary embolism
24/07/2020
TA346: Aflibercept for treating diabetic macular oedema
23/07/2020
TA345: Naloxegol for treating opioid‑induced constipation
23/07/2020
TA433: Apremilast for treating active psoriatic arthritis (replaced TA372)
21/07/2020
TA378: Ramucirumab for treating advanced gastric cancer or gastro–oesophageal junction adenocarcinoma previously treated with chemotherapy
21/07/2020
TA419: Apremilast for treating moderate to severe plaque psoriasis (replaced TA368)
21/07/2020
TA365: Ombitasvir–paritaprevir–ritonavir with or without dasabuvir for treating chronic hepatitis C
21/07/2020
TA350: Secukinumab for treating moderate to severe plaque psoriasis
21/07/2020
TA370: Bortezomib for previously untreated mantle cell lymphoma
21/07/2020
TA369: Ciclosporin for treating dry eye disease that has not improved despite treatment with artificial tears
14/07/2020
TA161: Raloxifene and teriparatide for the secondary prevention of osteoporotic fragility fractures in postmenopausal women
Follow AWTTC: